UBS raises Mondelez stock price target to $68 on earnings beat By Investing.com
UBS raised its price target for Mondelez International (NASDAQ:MDLZ) to $68 from $64 and kept a Neutral rating after the company’s Q2 results. Mondelez reported adjusted EPS of $0.73 versus UBS $0.67 and consensus $0.68, helped by organic sales growth, gross margin, and tax rate. It lifted organic sales outlook to at least 2% growth.
How this was made
The 30-second read
Why it matters
For traders, the key actionable signal is the fresh analyst price target ($68 vs $64) tied to raised organic sales guidance (at least 2% growth) after Q2 results beat estimates.
Market read
A concrete sell-side PT increase following an earnings beat and guidance raise can move near-term sentiment, but UBS’s caveats about 2027 earnings visibility suggest limited upside conviction.
What to watch
UBS explicitly questions what constitutes reasonable 2027 earnings expectations and notes positioning and broader staples outperformance could cap upside, which may reduce follow-through buying.
Background
The article centers on UBS’s post-earnings adjustment to Mondelez’s valuation view, citing a Q2 EPS beat and an organic sales outlook upgrade.
Ticker impact
UBS raised Mondelez’s price target to $68 after Q2 EPS of $0.73 beat forecasts and the company lifted organic sales outlook to at least 2% growth.
Likely modest positive bias for MDLZ as traders price in the higher target, with upside capped by questions around 2027 earnings visibility.
The article provides a concrete PT change tied to an earnings beat and guidance raise, but also notes UBS’s caution that sector outperformance and positioning may limit upside and that 2027 earnings expectations remain unclear.
Market effects
Supports the staples read-through that earnings beats and raised organic growth outlooks can still drive analyst PTs, even if sector positioning limits upside.
No direct regional catalyst beyond the opening mention of KOSPI; the actionable item is MDLZ-specific.
Limited; the news is primarily an analyst reaction to a US-listed consumer staples earnings print.
Counterpoint
The PT raise may not translate into sustained upside if the market already expects resilient staples demand and if 2027 earnings growth assumptions are overstated.
Key entities
- companyMondelez International
UBS raised its price target to $68 after Q2 EPS beat and the company lifted organic sales outlook to at least 2% growth.
- analyst_firmUBS
Maintained a Neutral rating while increasing the price target, citing improved organic sales, gross margin, and tax rate.
